Philipp B Staber

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/827711/publications.pdf

Version: 2024-02-01

103 papers	3,495 citations	172457 29 h-index	149698 56 g-index
105 all docs	105 docs citations	105 times ranked	6450 citing authors

#	Article	IF	Citations
1	Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncology, The, 2009, 10, 855-864.	10.7	620
2	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nature Medicine, 2016, 22, 1488-1495.	30.7	195
3	Translational regulation mechanisms of AP-1 proteins. Mutation Research - Reviews in Mutation Research, 2009, 682, 7-12.	5.5	186
4	Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Molecular Cancer Therapeutics, 2006, 5, 2203-2210.	4.1	141
5	Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. Lancet Haematology,the, 2017, 4, e595-e606.	4.6	130
6	Sustained PU.1 Levels Balance Cell-Cycle Regulators to Prevent Exhaustion of Adult Hematopoietic Stem Cells. Molecular Cell, 2013, 49, 934-946.	9.7	127
7	C/EBPa controls acquisition and maintenance of adult haematopoietic stem cell quiescence. Nature Cell Biology, 2013, 15, 385-394.	10.3	121
8	PDGFR blockade is a rational and effective therapy for NPM-ALKâ€“driven lymphomas. Nature Medicine, 2012, 18, 1699-1704.	30.7	113
9	Sox4 Is a Key Oncogenic Target in C/EBPÎ± Mutant Acute Myeloid Leukemia. Cancer Cell, 2013, 24, 575-588.	16.8	112
10	Hematopoietic Differentiation Is Required for Initiation of Acute Myeloid Leukemia. Cell Stem Cell, 2015, 17, 611-623.	11.1	97
11	Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). Journal of Clinical Oncology, 2022, 40, 242-251.	1.6	90
12	Two Transforming C-RAF Germ-Line Mutations Identified in Patients with Therapy-Related Acute Myeloid Leukemia. Cancer Research, 2006, 66, 3401-3408.	0.9	84
13	Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood, 2019, 134, 1132-1143.	1.4	81
14	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. Cancer Discovery, 2022, 12, 372-387.	9.4	77
15	Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia. Oncogene, 2004, 23, 894-904.	5.9	76
16	MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation. Blood, 2007, 109, 3500-3504.	1.4	68
17	WaldenstrÃ¶mâ€™s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, iv41-iv50.	1.2	63
18	First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. Blood, 2017, 130, 2499-2503.	1.4	59

#	Article	IF	Citations
19	Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplantation, 2008, 42, 275-279.	2.4	58
20	Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized Trial. Biology of Blood and Marrow Transplantation, 2012, 18, 1716-1726.	2.0	55
21	When the guardian sleeps: Reactivation of the p53 pathway in cancer. Mutation Research - Reviews in Mutation Research, 2017, 773, 1-13.	5.5	47
22	Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. Blood, 2010, 115, 2901-2909.	1.4	46
23	[68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia. Investigative Radiology, 2018, 53, 403-408.	6.2	45
24	Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation, 2005, 35, 889-893.	2.4	43
25	Myocardial Dysfunction and Male Mortality in Peroxisome Proliferator-Activated Receptor Alpha Knockout Mice Overexpressing Lipoprotein Lipase in Muscle. Laboratory Investigation, 2003, 83, 259-269.	3.7	41
26	Management of sepsis in neutropenia: guidelines of the infectious diseases working party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Annals of Hematology, 2006, 85, 424-433.	1.8	41
27	Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. Leukemia, 2019, 33, 696-709.	7.2	40
28	Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib. Leukemia, 2017, 31, 1117-1122.	7.2	36
29	A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial. Blood, 2021, 138, 71-71.	1.4	36
30	Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL. Nature Chemical Biology, 2019, 15, 232-240.	8.0	34
31	The Runx-PU.1 pathway preserves normal and AML/ETO9a leukemic stem cells. Blood, 2014, 124, 2391-2399.	1.4	32
32	CXCR4 PET imaging of mantle cell lymphoma using [⁶⁸Ga]Pentixafor: comparison with [¹⁸F]FDG-PET. Theranostics, 2021, 11, 567-578.	10.0	26
33	Posaconazole in the management of refractory invasive fungal infections. Therapeutics and Clinical Risk Management, 2008, Volume 4, 747-757.	2.0	25
34	Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. EBioMedicine, 2017, 26, 17-24.	6.1	24
35	[18F]FDG-PET/CT Radiomics for Prediction of Bone Marrow Involvement in Mantle Cell Lymphoma: A Retrospective Study in 97 Patients. Cancers, 2020, 12, 1138.	3.7	24
36	Ultra-early response assessment in lymphoma treatment: [18F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72Âhours of treatment. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 931-940.	6.4	23

#	Article	IF	Citations
37	BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. Blood, 2021, 137, 3495-3506.	1.4	22
38	Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma. Blood, 2020, 136, 32-33.	1.4	20
39	Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML. Blood, 2021, 138, 1331-1344.	1.4	19
40	CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis. Blood, 2018, 132, 1936-1950.	1.4	18
41	All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia. Cell Death and Disease, 2019, 10, 944.	6.3	18
42	RUNX1-ETO: Attacking the Epigenome for Genomic Instable Leukemia. International Journal of Molecular Sciences, 2019, 20, 350.	4.1	17
43	RECIL Versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients. Cancers, 2020, 12, 9.	3.7	15
44	The impact of <scp>COVID</scp>â€19 on cancer care of outpatients with low socioeconomic status. International Journal of Cancer, 2022, 151, 77-82.	5.1	15
45	Antifungal management in cancer patients. Wiener Medizinische Wochenschrift, 2007, 157, 503-510.	1.1	14
46	UGT2B17 modifies drug response in chronic lymphocytic leukaemia. British Journal of Cancer, 2020, 123, 240-251.	6.4	13
47	mRNA expression patterns indicate CD30 mediated activation of different apoptosis pathways in anaplastic large cell lymphoma but not in Hodgkin's lymphoma. Leukemia Research, 2006, 30, 343-348.	0.8	12
48	Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30â€positive aggressive lymphomas. European Journal of Haematology, 2020, 104, 251-258.	2.2	12
49	IL2RA Promotes Aggressiveness and Stem Cellâ€“Related Properties of Acute Myeloid Leukemia. Cancer Research, 2020, 80, 4527-4539.	0.9	12
50	Core-binding factor leukemia hijacks the T-cellâ€“prone PU.1 antisense promoter. Blood, 2021, 138, 1345-1358.	1.4	12
51	Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. HemaSphere, 2021, 5, e536.	2.7	11
52	Cannabinoid Receptors Are Overexpressed in CLL but of Limited Potential for Therapeutic Exploitation. PLoS ONE, 2016, 11, e0156693.	2.5	11
53	Severe thrombocytopenia due to host-derived anti-HPA-1a after non-myeloablative allogeneic haematopoietic stem cell transplantation for multiple myeloma: a case report. Vox Sanguinis, 2005, 89, 257-260.	1.5	9
54	Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk. Wiener Klinische Wochenschrift, 2020, 132, 97-109.	1.9	9

#	Article	IF	Citations
55	DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks. Clinical Cancer Research, 2022, 28, 756-769.	7.0	9
56	Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era. Cancers, 2021, 13, 5592.	3.7	9
57	Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI. ESMO Open, 2019, 4, e000538.	4.5	7
58	Targeting Nuclear NOTCH2 by Gliotoxin Recovers a Tumor-Suppressor NOTCH3 Activity in CLL. Cells, 2020, 9, 1484.	4.1	7
59	In Human Visualization of Ibrutinib-Induced CLL Compartment Shift. Cancer Immunology Research, 2020, 8, 984-989.	3.4	7
60	Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. Haematologica, 2021, 106, 2251-2256.	3.5	7
61	Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial). Blood, 2019, 134, 1754-1754.	1.4	7
62	Genes Regulated by NPM-ALK Fusion Kinase Play a Key Role in the Activation of AP-1 Transcription Factors.. Blood, 2004, 104, 245-245.	1.4	7
63	Metabolic drug survey highlights cancer cell dependencies and vulnerabilities. Nature Communications, 2021, 12, 7190.	12.8	7
64	Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor. Leukemia and Lymphoma, 2021, 62, 3440-3451.	1.3	6
65	Latent structure and measurement invariance of the Hospital Anxiety and Depression Scale in cancer outpatients. International Journal of Clinical and Health Psychology, 2022, 22, 100315.	5.1	6
66	The DNA Ligase IV Syndrome R278H Mutation Impairs B Lymphopoiesis via Error-Prone Nonhomologous End-Joining. Journal of Immunology, 2016, 196, 244-255.	0.8	4
67	Evi1 Counteracts Anti-Leukemic and Stem Cell Inhibitory Effects of All-Trans Retinoic Acid on Flt3-ITD/Npm1c-Driven Acute Myeloid Leukemia Cells. Biomedicines, 2020, 8, 385.	3.2	4
68	A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial. Blood, 2019, 134, 2877-2877.	1.4	3
69	Ristocetin-Induced Platelet Aggregation for Monitoring of Bleeding Tendency in Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia. Blood, 2015, 126, 718-718.	1.4	3
70	Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in the Large Arteries of Lymphoma Patients under 50 Years of Age. Biology, 2021, 10, 1206.	2.8	3
71	High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial. Blood, 2021, 138, 72-72.	1.4	3
72	Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia. Haematologica, 2003, 88, ECR29.	3.5	3

#	Article	IF	Citations
73	The Boneâ€™s Role in Myeloid Neoplasia. International Journal of Molecular Sciences, 2020, 21, 4712.	4.1	2
74	EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for WaldenstrÃ¶mâ€™s Macroglobulinemia. HemaSphere, 2021, 5, e634.	2.7	2
75	Two-Cohort Phase II Study in R/R CLL (COSMOS): First Preliminary Safety and Efficacy Results of Anti-CD19 MOR208 Treatment in Combination with Venetoclax in Patients Who Discontinued Prior BTK Inhibitor Therapy. Blood, 2018, 132, 4433-4433.	1.4	2
76	Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax. Blood, 2019, 134, 807-807.	1.4	2
77	First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 3556-3556.	1.4	2
78	ASH 2014 highlights: new therapeutic concepts for T cell lymphomas. Memo - Magazine of European Medical Oncology, 2015, 8, 176-179.	0.5	1
79	Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia. Blood, 2019, 134, 3965-3965.	1.4	1
80	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. Blood, 2020, 136, 2-4.	1.4	1
81	New and Highly Efficient Therapy for Treatment NPM-ALK Associated Lymphomas. Blood, 2011, 118, 1659-1659.	1.4	1
82	Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR. Blood, 2019, 134, 4037-4037.	1.4	1
83	Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis. Neoplasia, 2021, 23, 1183-1191.	5.3	1
84	Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial. Blood, 2021, 138, 2639-2639.	1.4	1
85	T-Cell Large Granular Lymphocyte Leukemia: An Interdisciplinary Issue?. Frontiers in Oncology, 2022, 12, 805449.	2.8	1
86	Sox4 Is a Key Oncogenic Target in C/EBPÎ± Mutant Acute Myeloid Leukemia. Cancer Cell, 2014, 25, 257.	16.8	0
87	Precision Medicine Concepts in T-Cell Lymphoma. , 0, , .		0
88	Blood cancer driver Musashi-2 as therapeutic target in chronic lymphocytic leukemia. Leukemia, 2021, 35, 982-983.	7.2	0
89	Two Novel Activating Germline Mutations of the C-RAF Proto-Oncogene Predisposing to Solid Tumors and Therapy-Related Acute Myeloid Leukemia.. Blood, 2004, 104, 3370-3370.	1.4	0
90	NPM-ALK Fusion Tyrosine Kinase of Anaplastic Large Cell Lymphoma Exerts Its Transforming Potential by Increasing Translation of JUNB through mTOR and S6K1.. Blood, 2006, 108, 1428-1428.	1.4	0

#	Article	IF	Citations
91	Adding Palifermin in Allogeneic and Autologous Stem Cell Transplantation Resulted in Reduced Oral Mucositis and Enhanced Intestinal Mucosal Recovery Measured by Citrulline Serum Levels.. Blood, 2006, 108, 5251-5251.	1.4	0
92	NPM-ALK Converts JUNB from a Tumor Suppressor to an Oncogene.. Blood, 2006, 108, 1448-1448.	1.4	0
93	Aberrant Somatic Hypermutation of Follicular Lymphoma Transformed To Diffuse Large B-Cell Lymphoma.. Blood, 2006, 108, 2413-2413.	1.4	0
94	Identification of Critical Phosporylation Sites within NPM-ALK That Regulate JUNB mRNA Translation.. Blood, 2007, 110, 3571-3571.	1.4	0
95	Autoregulation of the Transcription Factor PU.1 Via Its Evolutionarily Conserved Upstream Regulatory Element Is Critical in Adult Mouse Hematopoiesis.. Blood, 2009, 114, 1468-1468.	1.4	0
96	Runx1 Induced Chromatin Folding of the PU.1 Gene Locus Is Necessary for Adult Long-Term Hematopoietic Stem Cell Maintenance. Blood, 2011, 118, 2364-2364.	1.4	0
97	PU.1 Is a Downstream Target of C/EBPÎ± in Normal Hematopoiesis and Acute Myeloid Leukemia. Blood, 2011, 118, 1353-1353.	1.4	0
98	Identification of Sox4 As Key Oncogene in Leukemias with Mutated or Silenced C/EBPÎ±. Blood, 2012, 120, 114-114.	1.4	0
99	Sociology of Normal Stem and Progenitor Cells in CML Niche. Blood, 2012, 120, 1234-1234.	1.4	0
100	In Human Visualization of Ibrutinib-Induced CLL Compartment Shift. Blood, 2019, 134, 1750-1750.	1.4	0
101	Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells. Blood, 2020, 136, 40-41.	1.4	0
102	Metabolic Drug Survey Highlights Cancer Cell Dependencies and Vulnerabilities. Blood, 2020, 136, 26-27.	1.4	0
103	New frontiers in chronic lymphocytic leukemia on the way to curing the disease. Memo - Magazine of European Medical Oncology, 2022, 15, 3-3.	0.5	0